25 years’ experience in the biotechnology sector
Strong background in venture finance, business development and commercialisation
Brisbane, 3 April 2018 – Uniseed, a venture fund operating at the Universities of Melbourne, New South Wales, Sydney and Queensland, and the CSIRO, is pleased to announce that Dr Kathy Nielsen has joined the Board of its recently formed investee company Kinoxis Therapeutics Pty Ltd.
Kathy is a senior executive with a career spanning over 25 years in the biomedical/pharma sector. She has a strong track record in venture finance, business development and commercialisation, overlaid on a solid research background with a core specialty in drug discovery and intellectual property strategy. Kathy’s “hands on” experience from concept through to product development (preclinical, clinical, non-clinical) covers a wide range of therapeutic areas including cancer, autoimmune diseases, CNS diseases, cardiovascular and metabolic diseases, orthopaedics and respiratory disease.
Kathy was previously Senior Investment Manager at Queensland Investment Corporation where she managed numerous investments in new ventures across four venture capital funds. She currently manages the commercialisation of the life sciences portfolio at Monash University.
Uniseed CEO and Kinoxis Chairman Peter Devine commented; “We are very pleased to have Kathy join the Board of Kinoxis. The experience she brings across drug development, business development and venture finance will complement the existing Board and further help position the Company for success as it moves its drug development program forward.”
< ENDS >
Uniseed (www.uniseed.com) is a venture fund operating at the Universities of Melbourne, Queensland, New South Wales and Sydney, as well as the CSIRO. Uniseed’s mandate is to facilitate the commercialisation of research partner generated intellectual property by targeted investment in highly promising technologies. Uniseed’s investments cover a range of technology sectors. To date, the fund has exited a number of investments; a drug to treat nerve pain (Spinifex Pharmaceuticals acquisition by Novartis); a drug in development to treat fibrosis (Fibrotech Therapeutics sale to Shire plc); an IT security technology (Vintela sale to Quest Software Inc.); a semi‐ conductor technology (Fultec sale to Bourns Semiconductor Inc); and a headlice treatment (Hatchtech) sold to Dr Reddy’s Laboratories.
About Kinoxis Therapeutics
Kinoxis is a drug development company focused on the development of potential new therapies for substance use disorders, including alcohol, illicit and prescription drugs. It is a spin-out of the University of Sydney from research conducted at the School of Chemistry and School of Psychology.
For more information:
Peter Devine, CEO
+61 409 631 581
Hugh Alsop, CEO
+61 439 080 353